ArticleNutrition research and practice2026
Isothiocyanates inhibit the cisplatin-induced apoptosis and inflammation in human kidney HEK-293 cells.
Article in Nutrition research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCisplatin is a widely used drug clinically for the treatment of numerous solid malignant tumors. However, the use of cisplatin has resulted in serious side effects, of which renal toxicity and renal dysfunction are the most common. In this study, we explored the effect of isothiocyanates in cisplatin-treated human embryonic kidney (HEK)-293 cells. Allyl isothiocyanate (AITC) and benzyl isothiocyanate (BITC) are substances found in cruciferous vegetables such as watercress and broccoli. They possess various physiological activities including anti-inflammatory, anticancer and antioxidant. However, the protective effect of AITC and BITC against cisplatin-induced nephrotoxicity has not yet been elucidated. MATERIALS/
methodsHEK-293 cells were treated with cisplatin (50 µM) in AITC and BITC (0.3-1.25 µM) in the absence or presence for 24 h. MTT assays detected cell viability, and Hoechst 33342 staining allowed us to observe nuclear morphology changes such as chromatin condensation and apoptotic nuclei. Reactive oxygen species (ROS) detection assays measured intracellular ROS production and the griess reaction assays assessed nitric oxide (NO) production. Western blotting and quantitative polymerase chain reactions quantified corresponding proteins and mRNA.
resultsCisplatin treatment for 24 h increased the generation of intracellular ROS and NO production compared to untreated cells. In contrast, pretreatment with AITC and BITC significantly reduced intracellular ROS generation and NO production. AITC and BITC also significantly inhibited cisplatin-induced inflammation-related genes expression. AITC and BITC decreased cisplatin-induced mitogen-activated protein kinase (MAPK) protein expression. Pretreatment of cells with AITC and BITC in cisplatin-treated cells downregulated the Bax/Bcl-2 expression ratio, resulting in a dose-dependent inhibition of apoptosis.
conclusionOur results suggest that the inhibition of inflammation and cell death via MAPK signaling in HEK-293 cells plays a protective role in kidney damage. Therefore, AITC and BITC may be potential candidates to attenuate and prevent the onset and progression of nephrotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.